Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Med. 2024 May 10;5(5):380-382. doi: 10.1016/j.medj.2024.03.011.
Wagenlehner and colleagues demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. A major area of interest in real-world application of cefepime/taniborbactam is its potential role in treating carbapenem-resistant infections, which deserves further investigation.
Wagenlehner 和同事证明了头孢吡肟/他唑巴坦相对于美罗培南在治疗成人由碳青霉烯类敏感革兰氏阴性菌引起的复杂性尿路感染和急性肾盂肾炎的复合终点（微生物学加临床）方面具有非劣效性和优越性。头孢吡肟/他唑巴坦在实际应用中的一个主要关注点是其在治疗碳青霉烯类耐药感染方面的潜在作用，这值得进一步研究。
